GRx+Biosims 2022
7−9 November 2022
Bethesda North Marriott Hotel and Conference Center
North Bethesda, Maryland, USA
- Home
-
Generics
News
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
- Cancer and diabetes generic treatments receive positive opinion from EMA’s CHMP
Research
- The cost of developing drugs and use of generics
- Re-evaluation of the use of generics, especially when treating conditions such as epilepsy
- Repurposing generic drugs can save time and money
- Availability of medicines and the sustainable development of the national health system in Russia
-
Biosimilars
News
- Lucentis biosimilars approved in the UK and Korea
- New adalimumab biosimilars prepare to launch in Canada, US and Europe
- FDA approves Amneal’s bevacizumab biosimilar
- Europe: positive opinion for Inpremzia and Truvelog Mix 30 and Stimufend authorized
Research
- Patient perspectives on biosimilars in a high uptake country
- Biosimilar adoption and prescribing in Japan: a physician opinion survey
- Innovent and Eli Lilly announce final results for sintilimab plus biosimilar bevacizumab injection
- Totality of evidence supporting approval of Avsola in the treatment of IBD
- MORE EDITORIAL SECTIONS
- Search
Post your comment